AMST · Amesite Inc.

Amesite Inc. has strategically pivoted from education technology to AI-driven healthcare solutions, centering on its NurseMagic™ brand that addresses post-acute care challenges like documentation, compliance, and workflow efficiency through B2C direct-to-practitioner apps and B2B enterprise platforms. This shift, completed in fiscal 2025, targets underserved segments including skilled nursing, home health, and hospice, leveraging a modern tech stack for rapid feature deployment—at least five new capabilities weekly—and HIPAA-compliant workflows. The company's B2C free tier drives user feedback and adoption, feeding into enterprise sales motions that emphasize ROI from time savings and retention improvements. With 14 U.S. patents and trademarks like NURSEMAGIC℠, Amesite claims intellectual property protection around its AI platform, though it faces fierce competition from established EMR providers, agile mid-market players, and well-funded AI newcomers, all with larger resources and installed bases.

Financially, Amesite remains pre-revenue at scale, posting net losses of $3.6 million in FY2025 (down from $4.4 million in FY2024) amid ongoing cash burn and substantial going concern doubts. Management flags insufficient cash for the next 12 months, relying on equity financings subject to volatile market conditions. Recent private placements, including insider-led transactions closing April 28, 2026, issued warrants underlying the 4.8 million shares registered here, potentially yielding up to $5.38 million if fully exercised in cash—though beneficial ownership caps at 4.99% (waivable to 9.99%) limit immediate dilution and control shifts. Pre-offering shares stand at 5.43 million, ballooning to 10.27 million post-exercise, representing severe dilution for existing holders. Nasdaq compliance hangs in balance after a October 2025 deficiency notice for sub-$2.5 million equity; the company expects recent raises to cure this by April 2026 but faces ongoing monitoring and delisting risks that could slash liquidity and access to capital.

This S-1 registers resale shares for institutional holders like Armistice Capital and Intracoastal (each ~1.74 million shares), placement agents affiliated with H.C. Wainwright, and insiders including CEO Ann Marie Sastry (8.66% post-offering) and director George Parmer (3.20%). No direct proceeds flow to Amesite from resales, but exercises bolster the balance sheet. Governance features amplify control: a classified board with staggered terms, 66 2/3% supermajority votes for amendments/removals, stockholder advance notice rules, no written consents, and exclusive Delaware Chancery forum provisions, alongside Section 203 anti-takeover protections, entrench management against activism. Operating with just 6 employees and 2 consultants underscores lean execution but heightens key-person risks, particularly around the CEO. Cybersecurity vulnerabilities in handling health data, regulatory hurdles (HIPAA, state privacy laws), and failure to scale adoption amid economic pressures loom as existential threats, potentially derailing the pivot's promise in a high-growth but compliance-heavy market.